ACN Newswire

Professor Lin Xiang Xiong Hosts Landmark Art Exhibition and Peace Prize Ceremony in Paris

“The Vicissitudes of Life” Celebrates the Transformative Power of Art in Dialogue, Reflection and PeacebuildingPENANG, Malaysia, Sept 17, 2025 - (ACN Newswire via SeaPRwire.com) - Renowned humanitarian-artist Professor Lin Xiang Xiong (“Professor Lin”) and founder of the Lin Xiang Xiong Art Gallery in Penang, presented his latest exhibition, “The Vicissitudes of Life”, at the historic Hôtel de l’Industrie in Paris from 10 to 13 September 2025.(L-R) Jean-Pierre Raffarin, former French Prime Minister and founder of Lin Xiang Xiong Art Gallery, Professor Lin Xiang XiongThe exhibition received strong support from key French institutions, with former French President François Hollande serving as Honorary Patron, and former French Prime Minister Jean-Pierre Raffarin personally attending the opening. Featuring 25 original works by Professor Lin, the exhibition explored three themes - anti-war, anti-poverty, and anti-pollution - and vividly embodied Professor Lin’s vision of “Art for Peace”, a concept that transcends aesthetics and seeks to inspire moral reflection and intercultural understanding.Distinguished speakers exchange views on art, culture, and peace during the academic symposium held as part of Professor Lin Xiang Xiong’s exhibition “The Vicissitudes of Life” in Paris.During the exhibition, a high-level academic symposium was held, bringing together leading international scholars, philosophers, and cultural leaders to reflect on “Intercultural Dialogue at the Crossroads” and “Rebuilding the Concept of Peace through Art.” Distinguished speakers included French writer and human rights activist Marek Halter, eminent philosopher and sinologist François Jullien, intellectual publisher François L’Yvonnet, Swiss curator and sociologist Barbara Polla, special adviser to the President of the Arab World Institute Claude Mollard, cultural diplomacy advisor Yves Marek, and retired French Air Force General Étienne Copel. Throughout the discussions, Professor Lin shared his unique insights on the times, on art, and on the essence of peace, sparking strong resonance and deep dialogue.On 12 September, the inaugural “Lin Xiang Xiong Art for Peace Prize” ceremony was held with great success. The competition drew 1,883 entries from 100 countries around the world, far exceeding expectations. This overwhelming response underscored the wide recognition of Professor Lin’s “Art for Peace” advocacy, echoing the common aspirations of today’s world. Professor Lin announced that the award will be established as a biennial event, continuing as a major artistic initiative dedicated to peace.The exhibition and symposium attracted a full house at the historic Hôtel de l’Industrie in Paris.“This exhibition is more of an awakening of thought than a presentation of art,” said Professor Lin Xiang Xiong. “Every brushstroke is a testimony of time, a silent dialogue between past and present, pain and healing. Whether through the exhibition or the establishment of the Peace Prize, I hope art is not merely for admiration but can truly touch hearts, serve as a bridge between cultures, and awaken the soft conscience deep within humanity.”Exhibition view of “The Vicissitudes of Life”The exhibition also marks a milestone in Professor Lin’s artistic journey and heralds the opening of the Lin Xiang Xiong Art Gallery in Penang, scheduled for mid-December 2025. Covering 8,000 square meters, the gallery will house Professor Lin’s major works and also providing a platform for emerging artists to pursue their dreams. It will stand as one of the largest private art galleries in the region, strengthening Malaysia’s role as a hub of cultural diplomacy and intercultural understanding in Southeast Asia.Through “The Vicissitudes of Life,” Professor Lin once again demonstrates that art is a messenger of thought and conscience. With clarity, he advocates peace, and as an artist, he chooses his own path - through the soft power of culture, through words, and through his brush - to voice his deep concern for war, pollution, and poverty. With art as his language, he calls upon fellow artists to join his cause, uniting their strength to speak out for peace and the future of humanity.Download high-resolution images from this LINK.About Lin Xiang XiongProfessor Lin Xiang Xiong is a renowned artist, entrepreneur, and advocate for global security through art. As President of the Global Chinese Arts & Culture Association, a researcher at the Chinese Academy of Art, and a visiting Professor at Peking University, Lin's work crosses disciplines and borders, connecting Eastern and Western cultures.After leaving China for Singapore in 1956, Lin pursued art studies at the Academy of Arts (1965–1968). Success in business, particularly in the mining industry in Malaysia, funded his travels, art remained his personal refuge and lifelong passion.His painting style is a dynamic combination of abstraction, traditional techniques, and contemporary social commentary, touching on themes such as climate change, war, forced migration, and the human condition. Despite being involved in the commercial field, Lin has never neglected his commitment to art as a force for good.Professor Lin is an outspoken advocate of the power of the arts in promoting peace and unity. In 2016, he curated a UNESCO exhibition titled "Art for Peace – Cultural Dialogue between East and West", which calls on artists to rise up as peacemakers, reduce inequality, and protect the planet. These events resulted in important cultural dialogues that have been documented and archived by UNESCO. Professor Lin has published numerous works, including 8 collections of paintings and 27 volumes of essay and art criticism.For media information, kindly contact:Triven Marketing Group, for Lin Xiang Xiong Art GalleryJazzmin WanTel: +6 017 289 4110Email: j.wan@swanconsultancy.biz Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Business

Opendoor新CEO：一个转折点？

(SeaPRwire) -   房地产市场的重要参与者Opendoor Technologies Inc.最近任命了一位新任首席执行官。此次领导层变动对于该公司而言正值关键时刻，因为它正寻求在竞争激烈的房地产行业中巩固其地位。公司决定引入新领导者被视为一项战略举措，旨在应对未来的挑战和机遇。 这位新任首席执行官的背景包括在技术驱动的业务转型方面拥有丰富经验，预计将带领Opendoor迈入增长和创新的新时代。此次领导层调整反映了公司致力于提升其技术能力和扩大市场份额的承诺。随着房地产市场的发展，技术的作用变得越来越重要，Opendoor正在定位自身，以利用这些进步获得竞争优势。 Opendoor的商业模式侧重于利用技术简化房屋买卖流程，这在传统房地产行业中一直是一种颠覆性力量。通过提供无缝的在线交易平台，该公司旨在为客户提供便利和效率。在新任首席执行官的掌舵下，Opendoor有望进一步完善其平台，整合尖端技术以增强用户体验和运营效率。 新任首席执行官的任命也被视为一个加强公司战略伙伴关系并探索新增长途径的机会。近年来，Opendoor参与了各种合作和收购，以实现产品多样化并扩大市场范围。新领导层预计将在此基础上继续努力，培养能够推动长期成功的关系。 投资者和行业专家正在密切关注新任首席执行官将如何应对市场波动和监管变化带来的挑战。房地产市场受经济周期的影响，Opendoor适应这些动态的能力对其可持续性至关重要。此外，房地产行业的监管发展可能会影响公司的运营，因此领导层必须及时了解政策变化并相应调整战略。 Opendoor Technologies Inc. (NASDAQ:OPEN)正处于一个关键时刻，其新任首席执行官预计将在塑造公司未来方面发挥关键作用。此次领导层变动不仅对公司而言是一项重大事件，对更广泛的房地产行业也是如此，因为它反映了技术在房地产交易中日益增长的重要性。随着Opendoor开启新篇章，利益相关者们希望新领导层能够推动创新、增长和价值创造。 脚注： 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。 Opendoor近期任命首席执行官是其增强增长和创新战略的一部分。

ACN Newswire

7亿美元加注协鑫科技 发力技术迭代赋能落后产能出清

香港，2025年9月17日 - (亚太商讯 via SeaPRwire.com) – 9月16日，光伏高科技颗粒硅龙头协鑫科技（03800.HK）发布公告，宣布与有中东主权基金背景的国际知名投资机构无极资本（Infini Capital）达成战略融资协议，通过定向增发方式配售约47.36亿股，募集资金54.46亿港元，约合7亿美元，意向锁定6个月，进一步巩固公司股权结构安全稳定。公告显示，本次融资将主要用于三个方面：首先，用于供给侧改革的资金储备，推进多晶硅产能结构性调整；其次，强化第二曲线，以全球第一的硅烷气产能和产量，完成海外替代，在半导体集成电路对电子特气需求提升、TOPCon电池向BC电池转型对硅烷需求放量，锂电行业固态、半固态电池对硅烷的应用需求以及显示面板对硅烷气品质的高要求的多重背景下，以硅烷气打造协鑫新增长极；第三，优化公司资本结构，稳固股权结构护城河。一位分析师在接受记者采访时说： "当前多晶硅领域正在经历供给侧改革，但上游硅烷气的市场需求量却快速提升。光伏电池技术升级、储能应用以及集成电路、显示面板等领域对高品质硅烷气的需求持续增加，协鑫科技以此次融资为契机，开辟第二增长曲线，能够形成颗粒硅、硅烷气等多业务协同发展的新格局，在行业‘反内卷’的关键时期储备资金，赢得先机。"该分析师表示，通过资本赋能，协鑫科技在颗粒硅技术规模化应用、硅烷气产能和市场优势以及钙钛矿产业孵化之间形成良性互动，既巩固现有优势，又培育未来增长点，更能在全球能源转型中丰盈"反内卷"现金池，引领行业推动光伏产业供给侧改革。据悉，协鑫科技此次携手的无极资本双总部位于阿联酋阿布扎比和中国香港，有着多元化的投资布局，覆盖战略新兴科技、人工智能、人形机器人、智能制造等投资主题，已为中国高科技公司的快速发展提供超过100亿港元的资金支持。上述行业分析师指出，当前光伏行业正面临技术路线加速迭代与产能出清的关键节点。此次协鑫科技与无极资本携手，将有助于协鑫在现有基础上扩大竞争优势，高效辐射国内外高端市场，更可将碳排放优势转化为定价权，跳出"内卷"掣肘，在全球光伏市场供给侧改革中占据有利地位。此外，协鑫科技此次逆周期融资，也凸显其通过技术差异化持续打破行业同质竞争格局的战略意图，推动光伏行业告别低价内耗的"内卷"困境。"此次融资不仅优化了协鑫科技的资本结构，夯实了控股股东的地位，更关键的是为技术迭代以及推进落后产能出清提供了充足弹药，展现出国际投资机构对协鑫科技的信心。在行业‘反内卷’的关键时期，具备技术领先优势与充足现金储备的企业将获得更大议价和溢价空间。"上述分析师表示。协鑫科技相关负责人告诉记者，双方还将秉持协同发展与行业优化的共同目标，联合发起设立专项产业基金。该基金聚焦于整合行业内低效、低质的过剩产能，通过市场化收购、专业化重组及创新性升级等方式，推动资源向高质量产能集中，终结行业低价无序竞争乱象，缓解恶性"内卷"带来的资源浪费与发展压力，引导行业回归价值创造本质，构建健康有序、可持续发展的产业生态。财务数据显示，2025上半年，协鑫科技EBITDA（税息折旧及摊销前利润）约为3.8亿元，同比增长325.8%，守好了不亏现金的底线和基本盘。截至2025年二季度，颗粒硅平均生产现金成本（未含税）已降至25.31元/公斤，较今年一季度降低6.5%，继续保持行业最高水平，上半年公司颗粒硅产量市占率达到24.32%。上述分析师表示，随着国家整治光伏内卷、遏制无序竞争、依法保护知识产权等政策措施的力度加大，协鑫科技今年内在光伏行业里率先扭亏为盈胜券在握。截至9月15日收盘，协鑫科技报1.26港元/股，年内累计涨幅达16.67%。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

Karbon-X Corp. Files Year-End Financial Results

Calgary, Canada, Sept 17, 2025 - (ACN Newswire via SeaPRwire.com) - Karbon-X Corp. (OTCQX:KARX) (“Karbon-X" or the “Company”), a vertically integrated climate solutions company, today announced that it has filed its Form 10-K with audited financial results for the fiscal year ended May 31, 2025.The full filing is available under the Company’s profile on OTC Markets at www.otcmarkets.com/stock/KARX/overview  Operational and Strategic highlights for Fiscal Year 2025Completed the acquisition of ALLCOT Group, expanding Karbon-X’s global footprint and integrating world-class expertise.Launched trading operations, marking a critical milestone in validating the Company’s business model and initiating its revenue-generating activities. Entered landmark partnerships with major energy producers and with the BK Dukes, reflecting strong market confidence in Karbon-X’s vision and capabilities.Financial Highlights for Fiscal Year 2025  Revenue surged to $3.16 million, up from $0.41 million in the prior year, marking the first full year of active carbon credit trading.Recognized $3.86 million in deferred revenue from forward carbon credit contracts, including contracts acquired through the ALLCOT transaction.The ALLCOT acquisition expanded Karbon-X’s verified emissions pipeline and positioned the Company for multi-jurisdictional credit monetization. Entered revenue-generating agreements with major energy producers and the BK Dukes, contributing to $3.79 million in receivables from forward carbon credit sales.“2025 was a pivotal year for Karbon-X, marked by the acquisition of ALLCOT Group, the launch of our trading operations, and new partnerships that strengthened our position in the global carbon market. These achievements are reflected in our financial results, which highlight both the momentum we’ve built and the foundation we’ve established for long-term growth. We are confident in our strategy and committed to delivering lasting value for shareholders and the planet.” – Chad Clovis, CEO of Karbon-XLooking AheadThe Company intends to continue to execute on its growth strategy, with a focus on expanding its role in both compliance and voluntary carbon markets, advancing new partnerships, and scaling its portfolio of climate solutions. Management believes Karbon-X is well-positioned to capitalize on increasing demand for trusted climate solutions and to deliver long-term value for shareholders. About Karbon-XKarbon-X Corp. (OTCQX:KARX) is a vertically integrated climate solutions company delivering end-to-end climate solutions across both compliance and voluntary markets. From project origination and emissions quantification to third-party verification, credit issuance, and market distribution, Karbon-X ensures transparency and impact at every step. Karbon-X makes trusted climate action accessible not only to businesses and institutions, but also to individuals and everyday people who want their choices to create lasting impact.Forward Looking Statement This news release contains forward-looking statements, including but not limited to expectations related to Karbon-X Corp.’s financial performance, business strategy, growth plans, and market positioning. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements are subject to change, and Karbon-X Corp. assumes no obligation to update them, except as required by law.Contact: Adriana EbellInterim CFOKarbon-Xa.ebell@karbon-x.com Emma CaputoVP of MarketingKarbon-Xec@karbon-x.com  Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

JCN Newswire

EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes

HONG KONG, Sep 17, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for metabolic diseases, announced that data from the Phase 3 SYMPHONY 2 trial evaluating the safety and efficacy of HTD1801 in patients with type 2 diabetes mellitus (T2DM) is being presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.HTD1801, is a first-in-class anti-inflammatory metabolic modulator that activates AMPK and inhibits the NLRP3 inflammasome. These pathways converge at the nexus of metabolic dysregulation beyond glucose control and chronic inflammation. This randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of HTD1801 compared to placebo in patients with T2DM inadequately controlled with metformin. The primary endpoint of Symphony 2 was change from baseline in HbA1c to Week 24 compared to placebo. Secondary endpoints explored effects on cardiovascular, metabolic, and renal comorbidities to assess it’s potential as a comprehensive Cardiovascular-Kidney-Metabolic therapy.Eligible patients were randomized 2:1 to HTD1801 1000 mg BID (N=365) or placebo (N=184). The study met the primary endpoint at Week 24, with HTD1801-treated patients achieving an LS mean change in HbA1c of -1.21% compared to -0.68% with placebo (LS mean diff: -0.53, p<0.0001). 33% of HTD1801-treated patients achieved HbA1c <7% at Week 24 vs 11% with placebo (p<0.0001). Improvements in HbA1c with HTD1801 were parallelled with significant improvements in postprandial and fasting glucose at Week 24. In patients with mild renal impairment, HTD1801 improved eGFR, suggesting reno-protective potential. Significant reductions in lipids and inflammatory markers were also observed with HTD1801. Safety and tolerability were favorable and consistent with previous clinical trials of HTD1801. Serious AEs occurred in 4% vs 6% of patients with HTD1801 vs placebo, respectively. No patient experienced severe hypoglycemia during the study. An open-label extension is ongoing to confirm the durability of these benefits of HTD1801.Abstract Title: Symphony 2: A Randomized, Placebo-Controlled Phase 3 Study of Berberine Ursodeoxycholate in Patients with Type 2 Diabetes Inadequately Controlled with MetforminPresentation Number: 62Presentation Date/Time: Tuesday September 16, 2025 / 2:45pm CESTFormat: Oral PresentationPresenting Author: Linong Ji“HTD1801 is an innovative small-molecule drug with a novel dual mechanism of action, simultaneously activating AMPK and inhibiting the NLRP3 inflammasome.”said professor Linong Ji, the leading principal investigator for this Phase 3 clinical trial and former Vice President of the International Diabetes Federation (IDF), Director of the Peking University Diabetes Center and Director of the Department of Endocrinology and Metabolism, Peking University People’s Hospital, “In completed Phase 3 clinical trials, it demonstrated consistent and clinically meaningful glucose-lowering effects with a favorable safety profile. Beyond glycemic control, HTD1801 has also shown multiple additional benefits, including lipid reduction, attenuation of inflammation, and improvements in renal function. As an orally administered antidiabetic agent, HTD1801 uniquely provides both cardiometabolic risk factor modification and renal protection, underscoring its substantial potential and competitive advantage for further clinical development.”“The SYMPHONY 2 trial is our second Phase 3 study in type 2 diabetes to achieve its primary endpoint, underscoring the consistency and robustness of HTD1801’s clinical profile,” said Liping Liu, Founder, Chairwoman and CEO of HighTide Therapeutics. “We are particularly pleased that HTD1801 demonstrated not only glycemic benefit but potential cardiovascular and renal benefit in T2DM patients. With successful Phase 3 trials now in hand, we are well-positioned to submit our NDA in China later this year – marking a major step toward bringing a novel therapy to millions of patients who continue to face significant unmet needs in diabetes care.”About HTD1801HTD1801 is a first-in-class new molecular entity, addressing the residual risks of cardiovascular-kidney-metabolic (CKM) diseases. HTD1801 is an orally delivered, anti-inflammatory metabolic modulator that, as a single molecular entity, exhibits a unique dual mechanism of action through AMPK activation and NLRP3 inflammasome inhibition, both pathways working to mitigate dysfunctions associated with metabolic diseases. Multiple global clinical trial results have demonstrated comprehensive benefits of HTD1801, including improved insulin resistance, glycemic control, lipid lowering, renal benefit, weight loss, hepatic benefits, and anti-inflammatory effects. Therefore, HTD1801 has the potential to become a foundational CKM therapy.About HighTide TherapeuticsHighTide Therapeutics, Inc. (2511.HK) is an innovative biopharmaceutical company specializing in metabolic diseases. The company is dedicated to developing first-in-class breakthrough therapies, providing therapeutic solutions with comprehensive benefits for patients worldwide. HighTide Therapeutics has established a globally positioned product pipeline with 100% self-developed intellectual property. The company has conducted clinical studies for multiple indications across various countries and regions, and the outcomes of these studies have been well recognized by global academic community and regulatory bodies worldwide. HTD1801, HighTide Therapeutics’ lead asset, is a first-in-class dual-target new molecular entity. It has received two Fast Track designations and one Orphan Drug designation from the US Food and Drug Administration (FDA), and has been included twice in the National Major Science and Technology Project for Significant New Drug Development in China.For more information, please visit www.hightidetx.com, Contact: pr@hightidetx.com Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

ACN Newswire

EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes

HONG KONG, Sep 17, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for metabolic diseases, announced that data from the Phase 3 SYMPHONY 2 trial evaluating the safety and efficacy of HTD1801 in patients with type 2 diabetes mellitus (T2DM) is being presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.HTD1801, is a first-in-class anti-inflammatory metabolic modulator that activates AMPK and inhibits the NLRP3 inflammasome. These pathways converge at the nexus of metabolic dysregulation beyond glucose control and chronic inflammation. This randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of HTD1801 compared to placebo in patients with T2DM inadequately controlled with metformin. The primary endpoint of Symphony 2 was change from baseline in HbA1c to Week 24 compared to placebo. Secondary endpoints explored effects on cardiovascular, metabolic, and renal comorbidities to assess it’s potential as a comprehensive Cardiovascular-Kidney-Metabolic therapy.Eligible patients were randomized 2:1 to HTD1801 1000 mg BID (N=365) or placebo (N=184). The study met the primary endpoint at Week 24, with HTD1801-treated patients achieving an LS mean change in HbA1c of -1.21% compared to -0.68% with placebo (LS mean diff: -0.53, p<0.0001). 33% of HTD1801-treated patients achieved HbA1c <7% at Week 24 vs 11% with placebo (p<0.0001). Improvements in HbA1c with HTD1801 were parallelled with significant improvements in postprandial and fasting glucose at Week 24. In patients with mild renal impairment, HTD1801 improved eGFR, suggesting reno-protective potential. Significant reductions in lipids and inflammatory markers were also observed with HTD1801. Safety and tolerability were favorable and consistent with previous clinical trials of HTD1801. Serious AEs occurred in 4% vs 6% of patients with HTD1801 vs placebo, respectively. No patient experienced severe hypoglycemia during the study. An open-label extension is ongoing to confirm the durability of these benefits of HTD1801.Abstract Title: Symphony 2: A Randomized, Placebo-Controlled Phase 3 Study of Berberine Ursodeoxycholate in Patients with Type 2 Diabetes Inadequately Controlled with MetforminPresentation Number: 62Presentation Date/Time: Tuesday September 16, 2025 / 2:45pm CESTFormat: Oral PresentationPresenting Author: Linong Ji“HTD1801 is an innovative small-molecule drug with a novel dual mechanism of action, simultaneously activating AMPK and inhibiting the NLRP3 inflammasome.”said professor Linong Ji, the leading principal investigator for this Phase 3 clinical trial and former Vice President of the International Diabetes Federation (IDF), Director of the Peking University Diabetes Center and Director of the Department of Endocrinology and Metabolism, Peking University People’s Hospital, “In completed Phase 3 clinical trials, it demonstrated consistent and clinically meaningful glucose-lowering effects with a favorable safety profile. Beyond glycemic control, HTD1801 has also shown multiple additional benefits, including lipid reduction, attenuation of inflammation, and improvements in renal function. As an orally administered antidiabetic agent, HTD1801 uniquely provides both cardiometabolic risk factor modification and renal protection, underscoring its substantial potential and competitive advantage for further clinical development.”“The SYMPHONY 2 trial is our second Phase 3 study in type 2 diabetes to achieve its primary endpoint, underscoring the consistency and robustness of HTD1801’s clinical profile,” said Liping Liu, Founder, Chairwoman and CEO of HighTide Therapeutics. “We are particularly pleased that HTD1801 demonstrated not only glycemic benefit but potential cardiovascular and renal benefit in T2DM patients. With successful Phase 3 trials now in hand, we are well-positioned to submit our NDA in China later this year – marking a major step toward bringing a novel therapy to millions of patients who continue to face significant unmet needs in diabetes care.”About HTD1801HTD1801 is a first-in-class new molecular entity, addressing the residual risks of cardiovascular-kidney-metabolic (CKM) diseases. HTD1801 is an orally delivered, anti-inflammatory metabolic modulator that, as a single molecular entity, exhibits a unique dual mechanism of action through AMPK activation and NLRP3 inflammasome inhibition, both pathways working to mitigate dysfunctions associated with metabolic diseases. Multiple global clinical trial results have demonstrated comprehensive benefits of HTD1801, including improved insulin resistance, glycemic control, lipid lowering, renal benefit, weight loss, hepatic benefits, and anti-inflammatory effects. Therefore, HTD1801 has the potential to become a foundational CKM therapy.About HighTide TherapeuticsHighTide Therapeutics, Inc. (2511.HK) is an innovative biopharmaceutical company specializing in metabolic diseases. The company is dedicated to developing first-in-class breakthrough therapies, providing therapeutic solutions with comprehensive benefits for patients worldwide. HighTide Therapeutics has established a globally positioned product pipeline with 100% self-developed intellectual property. The company has conducted clinical studies for multiple indications across various countries and regions, and the outcomes of these studies have been well recognized by global academic community and regulatory bodies worldwide. HTD1801, HighTide Therapeutics’ lead asset, is a first-in-class dual-target new molecular entity. It has received two Fast Track designations and one Orphan Drug designation from the US Food and Drug Administration (FDA), and has been included twice in the National Major Science and Technology Project for Significant New Drug Development in China.For more information, please visit www.hightidetx.com, Contact: pr@hightidetx.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

TruMerit Adds Two More Global Credentials for Rehabilitation Care Workers

PHILADELPHIA, PA, Sept 17, 2025 - (ACN Newswire via SeaPRwire.com) - TruMerit, a global leader in healthcare workforce development, today launched two new global credentials for healthcare workers specializing in rehabilitation, habilitation, and restorative care.The Certified Global Health Worker-Rehabilitation (CGHW-R) and the Certified Global Health Worker-Rehabilitation Advanced (CGHW-RA) have been developed specifically for eligible health workers worldwide who wish to have their applied experience and competencies in rehab care recognized and verified by passing a certification examination. These credentials, along with the Certified Global Nurse-Rehabilitation (CGN-R) that TruMerit established last year, are intended to advance and improve services for the more than two billion people worldwide who need this care.The CGHW-RA credential was developed for those with a degree or diploma in a rehabilitation field. These include clinicians, educators, and instructors with physiotherapy, occupational therapy, speech language pathology, or other rehab-related specializations.The CGHW-R credential was designed for those who have rehab health experience but have not completed post-secondary education in an area of rehab specialization. These would include technicians, assistive personnel, nursing assistants, and home or community health aides working in rehabilitation, habilitation, and restorative care settings.In addition to education and degree requirements, candidates for these credentials must have at least two years of work experience in a rehabilitation, habilitation, or restorative care setting during the last five years. Upon verification of their credentials by TruMerit, they must pass a proctored exam that is offered at more than 1,000 test centers worldwide.In 2019, CARF International, a non-profit organization that accredits rehabilitation care providers worldwide, alerted TruMerit (known then as CGFNS International) about the growing demand for validating practice competence of the rehabilitation health workforce and raising standards across the care continuum. TruMerit and rehabilitation experts from across the world began the process to create exam-based global certifications for healthcare professionals working in rehabilitation, habilitation, and restorative care settings. The process has included more than 200 subject matter experts from 45 countries from all world regions and income levels."Caring for the huge and growing population of persons living with a disability is one of the most pressing issues facing healthcare today. By validating the knowledge and skills of those who devote their careers to providing this care, global credentials will help drive efforts to expand and equip this vital workforce to meet the challenges of the future. We are grateful to the global team of rehab care experts who helped make these credentials possible," said Julia To Dutka, Chief of TruMerit's Global Health Workforce Development Institute, which is leading the initiative.View more information on TruMerit's global rehab certification program.Additionally, last month TruMerit unveiled its Certified Global Nurse (CGN) credential for first-level, general nurses (RNs), along with a reinvented Nurse Qualifying Exam.About TruMeritTruMerit is a worldwide leader in healthcare workforce development. Formerly known as CGFNS International, the organization has a nearly 50-year history supporting the career mobility of nurses and other healthcare workers-and those who license and hire them-by validating their education, skills, and experience as they seek authorization to practice in the United States and other countries. As TruMerit, this mission has been expanded to building workforce capacity that meets the needs of people in a rapidly evolving global health landscape. Through its Global Health Workforce Development Institute, the organization is advancing evidence-based research, thought leadership, and advocacy in support of healthcare workforce development solutions, including globally recognized practice standards and certifications that will enhance career pathways for healthcare workers.Contact InformationDavid St. Johndstjohn@trumerit.orgSOURCE: TruMerit Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

EASD 2025 | 君圣泰医药口头报告HTD1801治疗2型糖尿病临床3期研究成果

香港，2025年9月17日 - (亚太商讯 via SeaPRwire.com) – 君圣泰医药（股票代码: 2511.HK），一家专注于开发多功能疗法以解决代谢性疾病未满足临床需求的创新药公司，宣布在第61届欧洲糖尿病研究协会（EASD）年会（奥地利维也纳），口头报告2型糖尿病（T2DM）患者中评估HTD1801有效性和安全性的3期临床研究（SYMPHONY 2）数据。HTD1801是全球首创抗炎代谢调节剂，通过激活AMPK并抑制NLRP3炎症小体的双重作用机制，为患者带来远超血糖控制的综合性代谢获益。这项随机双盲、安慰剂对照的临床研究旨在评估HTD1801与安慰剂相比在二甲双胍控制不佳的T2DM患者中的有效性和安全性。SYMPHONY 2的主要终点为与安慰剂相比治疗24周后HbA1c相对于基线的变化。次要终点包括对心血管、代谢及肾脏共病的危险因素干预，以评估HTD1801作为心肾代谢系统疾病（CKM）的综合治疗潜力。SYMPHONY 2试验中，患者按2:1随机分配至HTD1801组（1000mg一天两次，N=365）或安慰剂组（N=184）。该研究达到了主要终点，HTD1801治疗组第24周HbA1c的最小二乘（LS）均值变化为 -1.21%，安慰剂组为-0.68%（LS均值差异：-0.53%， p＜0.0001）。33%的患者在HTD1801治疗24周后达到HbA1c＜7%的控制目标，安慰剂组仅有11%（p＜0.0001）。治疗24周后，HTD1801还显著改善了餐后血糖和空腹血糖。事后分析显示在合并轻度肾损的患者中，HTD1801可改善eGFR，提示肾脏保护的潜力。此外，HTD1801显著降低了预设次级终点中血脂和炎症标志物。与之前临床研究结果一致，HTD1801表现出良好的安全性和耐受性。HTD1801组的严重不良反应发生率为4%，安慰剂组为6%。研究期间未发生严重低血糖事件。该研究对应的开放标签延长期试验正在进行中，将进一步验证HTD1801综合疗效的持久性。摘要标题：Symphony 2：一项评估HTD1801治疗二甲双胍控制不佳的2型糖尿病患者的随机、安慰剂对照的临床3期研究报告编号：62报告时间：2025年9月16日，周二，下午2:45（欧洲中部夏令时）报告形式：口头报告演讲者：纪立农 教授临床试验的主要研究者，前国际糖尿病联盟（IDF）副主席、北京大学糖尿病中心主任、北京大学人民医院内分泌和代谢科主任纪立农教授指出：“HTD1801 是一款具有源头创新性的小分子药物，具有独特的双重作用机制，能够同时激活 AMPK和抑制 NLRP3 炎症小体。在已经完成的3期临床研究中，该药物展现出非常平稳且显著的降糖效果而且安全性良好。除此之外，研究还观察到 HTD1801 具有降糖之外的多重获益，包括降低血脂水平、减轻炎症反应，以及改善肾脏功能等相关指标。作为一种口服降糖药物，HTD1801 在改善心血管危险因素与保护肾脏功能方面也展现出潜力，值得进一步探索其在心肾保护方面的潜力”君圣泰医药的创始人、董事长兼首席执行官刘利平博士表示：“SYMPHONY 2是我们在2型糖尿病领域开展的第二项3期临床研究，已成功达到主要临床终点，充分表明HTD1801临床疗效的一致性和可靠性。值得关注的是，HTD1801不仅展现出显著的血糖获益，同时在心血管和肾脏方面亦为T2DM患者带来潜在获益。随着3期临床试验的顺利进行，我们今年将在中国递交NDA申请，为广大糖尿病患者带来新的治疗选择，填补该疾病领域创新疗法重大未满足需求。”关于HTD1801HTD1801是一款全球首创的新分子实体，旨在解决心肾代谢系统疾病（CKM）。HTD1801是口服抗炎及代谢调节剂，作为单一分子具有独特双机制 ，通过激活AMPK及抑制NLRP3炎症小体发挥其生物学活性，有效解决代谢性疾病。全球多项临床结果验证HTD1801一药多效的特性，为患者带来综合获益，包括改善胰岛素抵抗、血糖控制、血脂降低、肾脏获益、体重减轻、肝脏获益及抗炎等。基于此，HTD1801有潜力成为CKM领域的基础性治疗药物。关于君圣泰医药君圣泰医药（股票代码：2511.HK）是一家专注于代谢性疾病的创新生物医药公司。立足源头创新，公司致力于开发代谢性疾病的突破性疗法，为全球患者提供标本兼治、综合获益的解决方案。公司已建立100%自主知识产权的全球化产品管线，已在多个国家和地区开展了针对多项适应症的临床研究，相关成果获得国际学术界和监管机构的认可。公司核心产品HTD1801是全球首创的双靶点新分子实体，已获得美国食品药品监督管理局（FDA）2项快速通道与1项孤儿药资格认定、以及2项“重大新药创制”国家科技重大专项。 更多信息，请访问公司官网：www.hightidetx.com， 或联系公司品牌部:  pr@hightidetx.com Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com